<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03178487</url>
  </required_header>
  <id_info>
    <org_study_id>M16-098</org_study_id>
    <secondary_id>2017-000431-14</secondary_id>
    <nct_id>NCT03178487</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis ( SELECT Axis 1 )</brief_title>
  <acronym>SELECT Axis 1</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2 multicenter, randomized, double-blind, placebo-controlled study to evaluate
      the safety and efficacy of upadacitinib in participants with active ankylosing spondylitis
      (AS).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Anticipated">November 11, 2020</completion_date>
  <primary_completion_date type="Actual">January 21, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with Assessment of SpondyloArthritis international Society (ASAS) 40 response</measure>
    <time_frame>At Week 14</time_frame>
    <description>It is defined as a &gt;= 40% improvement and an absolute improvement of &gt;= 2 units (on a scale of 0 to 10) from Baseline in at least three of the following four domains, with no worsening at all in the remaining domain:
Patient's Global Assessment
Pain
Function
Inflammation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI)</measure>
    <time_frame>Week 0 (baseline) and Week 14</time_frame>
    <description>The BASFI is a participant-reported measure that evaluates physical function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with ASAS partial remission (PR)</measure>
    <time_frame>Week 14</time_frame>
    <description>ASAS PR is defined as an absolute score of &lt;= 2 units for each of the four domains (patient's global assessment, pain, function and inflammation) identified in ASAS 40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Work Productivity and Activity Impairment (WPAI)</measure>
    <time_frame>Week 0 (baseline) and Week 14</time_frame>
    <description>The WPAI is a questionnaire used to evaluate lost productivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES)</measure>
    <time_frame>Week 0 (baseline) and Week 14</time_frame>
    <description>The MASES evaluation will be conducted to assess the presence or absence of enthesitis at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right), noting the participants' responses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS)</measure>
    <time_frame>Week 0 (baseline) and Week 14</time_frame>
    <description>The ASDAS tool is a self-administered questionnaire plus an objective laboratory evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMIlin)</measure>
    <time_frame>Week 0 (baseline) and Week 14</time_frame>
    <description>The BASMIlin will be conducted to evaluate spinal mobility in a participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ASAS 20 response</measure>
    <time_frame>At Week 14</time_frame>
    <description>ASAS 20 response is defined as an improvement of &gt;= 20% and absolute improvement of &gt;= 1 unit (on a scale of 0 to 10) from Baseline in at least three of the following four domains, with no deterioration (where deterioration is defined as a worsening of &gt;= 20% and a net worsening of &gt;= 1 units [on a scale of 0 to 10]) in the remaining domain:
Patient's Global Assessment
Pain
Function
Inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in magnetic resonance imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC) score (Spine)</measure>
    <time_frame>Week 0 (baseline) and Week 14</time_frame>
    <description>Six discovertebral units (DVU) representing the 6 most abnormal DVUs, and 3 consecutive sagittal slices at each DVU representing the most abnormal slices for that DVU are selected for scoring. Each DVU is divided into 4 quadrants and scored for the presence (1) or absence (0) of edema. The maximum score is 12 per DVU. The maximum score is 72 for 6 DVUs. If edema is present in at least 1 quadrant of a DVU slice, it is scored for intensity and depth of the edema representing that slice: A score of 1 is assigned if an intense signal were to be seen in any quadrant on a DVU slice. The maximum score for intensity per slice is 1, per DVU is 3 and for 6 DVUs is 18. A lesion is graded as deep (1) if there is a homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the surface of the endplate in any quadrant. The maximum score per slice is 1, for a DVU is 3 and for 6 DVUs is 18. The total maximum SPARCC score for all 6 DVUs is 108.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Ankylosing Spondylitis (AS) Quality of Life (QoL)</measure>
    <time_frame>Week 0 (baseline) and Week 14</time_frame>
    <description>This assess QOL in participants with AS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 response</measure>
    <time_frame>At Week 14</time_frame>
    <description>BASDAI 50 response is defined as 50% improvement in the Bath AS Disease Activity Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ASAS Health Index (HI)</measure>
    <time_frame>Week 0 (baseline) and Week 14</time_frame>
    <description>This is used to asses overall functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in MRI Spondyloarthritis Research Consortium of Canada (SPARCC) score Sacroiliac (SI) joints</measure>
    <time_frame>At Week 14</time_frame>
    <description>Six consecutive sacroiliac (SI) joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints are assessed for edema, intensity and depth of edema using SPARCC scoring. Each SI joint (left and right) is divided into quadrants for a total of 8 SI scoring locations. Each quadrant is scored for the presence (1) or absence (0) of edema; the maximum score is 8 per slice and maximum score for 6 SI joint slices is 48. Intensity of edema: A score of 1 is assigned for each SI joint (left and right) if an intense signal is seen in any quadrant of that joint for each slice. The maximum score is 2 per slice and 12 for 6 slices. A lesion is graded as deep (score of 1) if there is a homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The maximum score per slice is 2 and for 6 slices 12. The total maximum score for all SI joints across 6 slices is 72.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">187</enrollment>
  <condition>Ankylosing Spondylitis (AS)</condition>
  <arm_group>
    <arm_group_label>Participants receiving Upadacitinib dose A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receiving Upadacitinib dose A once daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants receiving placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receiving placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Participants receiving Upadacitinib dose A</arm_group_label>
    <other_name>ABT-494</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Upadacitinib Placebo</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Participants receiving placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant with a clinical diagnosis of Ankylosing Spondylitis (AS) and meeting the
             modified New York Criteria for AS.

          -  Participant must have baseline disease activity as defined by having a Bath Ankylosing
             Spondylitis Disease Activity Index (BASDAI) score &gt;= 4 and a Patient's Assessment of
             Total Back Pain score &gt;= 4 based on a 0 - 10 Numeric Rating Scale (NRS) at the
             Screening and Baseline Visits.

          -  Participant has had an inadequate response to at least two Nonsteroidal
             Anti-inflammatory Drugs (NSAIDs) over an at least 4-week period in total at maximum
             recommended or tolerated doses, or participant has an intolerance to or
             contraindication for NSAIDs as defined by the Investigator.

          -  If entering the study on concomitant Methotrexate (MTX), leflunomide, Sulfasalazine
             (SSZ), and/or hydroxychloroquine, participant must be on a stable dose of MTX (&lt;= 25
             mg/week) and/or SSZ (&lt;= 3 g/day) and/or hydroxychloroquine (&lt;= 400 mg/day) or
             leflunomide (&lt;= 20 mg/day) for at least 28 days prior to the Baseline Visit. A
             combination of up to two background conventional synthetic disease-modifying
             anti-rheumatic drugs (csDMARDs) is allowed except the combination of MTX and
             leflunomide.

          -  If entering the study on concomitant oral corticosteroids, participant must be on a
             stable dose of prednisone (&lt;= 10 mg/day), or oral corticosteroid equivalents, for at
             least 14 days prior to the Baseline Visit.

          -  If entering the study on concomitant NSAIDs, tramadol, combination of acetaminophen
             and codeine or hydrocodone, and/or non-opioid analgesics, participant must be on
             stable dose(s) for at least 14 days prior to the Baseline Visit.

        Exclusion Criteria:

          -  Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to
             tofacitinib, baricitinib, and filgotinib).

          -  Prior exposure to any biologic therapy with a potential therapeutic impact on
             spondyloarthritis (SpA).

          -  Intra-articular joint injections, spinal/paraspinal injection(s), or parenteral
             administration of corticosteroids within 28 days prior to the Baseline Visit. Inhaled
             or topical corticosteroids are allowed.

          -  Participant on any other DMARDs (other than those allowed), thalidomide or apremilast
             within 28 days or five half-lives (whichever is longer) of the drug prior to the
             Baseline Visit.

          -  Participant on opioid analgesics (except for combination acetaminophen/codeine or
             acetaminophen/hydrocodone which are allowed) or use of inhaled marijuana within 14
             days prior to the Baseline Visit.

          -  Participant has a history of inflammatory arthritis of different etiology other than
             axial SpA (including but not limited to rheumatoid arthritis, psoriatic arthritis,
             mixed connective tissue disease, systemic lupus erythematosus, reactive arthritis,
             scleroderma, polymyositis, dermatomyositis, fibromyalgia, or any arthritis with onset
             prior to 17 years of age.

          -  Laboratory values meeting the following criteria within the Screening period prior to
             the first dose of study drug: serum aspartate transaminase &gt; 2 × Upper Limit of Normal
             (ULN); serum alanine transaminase &gt; 2 × ULN; estimated glomerular filtration rate by
             simplified 4-variable Modification of Diet in Renal Disease formula &lt; 40 milliliter
             (mL)/minute/1.73m^2; hemoglobin &lt; 10 gram/deciliter, total white blood cell count &lt;
             2,500/microliter (μL); absolute neutrophil count &lt; 1,500/μL; absolute lymphocyte count
             &lt; 800/μL; and platelet count &lt; 100,000/μL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatolo /ID# 164446</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032-9306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis and Rheum Researc /ID# 165705</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032-9306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David S. Hallegua MD /ID# 165090</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covina Arthritis Clinic /ID# 165061</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Health System /ID# 166166</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Global Research Foundation /ID# 165130</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Center of San Diego /ID# 166167</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92128-2549</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Arthritis Associates /ID# 164444</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Arthritis and Osteo /ID# 165023</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LeJenue Research Associates /ID# 165202</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HMD Research LLC /ID# 205172</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32819</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Lukes Clinic /ID# 165827</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Special /ID# 164385</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System /ID# 165515</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aa Mrc Llc /Id# 165100</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Lawrence Health System /ID# 165025</name>
      <address>
        <city>Potsdam</city>
        <state>New York</state>
        <zip>13676</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DJL Clinical Research, PLLC /ID# 165044</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210-8508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Ctr Clinical Res /ID# 164470</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Ctr Reading /ID# 164876</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Arthritis Care, a division of Comprehensive Rheumatology Care PLLC /ID# 168107</name>
      <address>
        <city>Hendersonville</city>
        <state>Tennessee</state>
        <zip>37075-6213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Group Integrated He /ID# 165195</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arth and Osteo Clin Brazo Valley /ID# 165194</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital /ID# 169239</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritus Research /ID# 169240</name>
      <address>
        <city>Camberwell</city>
        <state>Victoria</state>
        <zip>3124</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent /ID# 166017</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ReumaClinic Genk /ID# 166018</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven /ID# 166019</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Research Assoc /ID# 165240</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5M 0H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta - Division of Rheumatology /ID# 165239</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Rheumatology /ID# 200087</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe de Recherche en Maladies Osseuses /ID# 165238</name>
      <address>
        <city>Sainte-foy</city>
        <state>Quebec</state>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Dubrava /ID# 167049</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Kuna-Peric /ID# 164851</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav Praha /ID# 167004</name>
      <address>
        <city>Prague 2</city>
        <state>Praha 2</state>
        <zip>128 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayerova nemocnice /ID# 167003</name>
      <address>
        <city>Prague 4</city>
        <state>Praha 4</state>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>REVMACLINIC s.r.o. /ID# 167171</name>
      <address>
        <city>Brno</city>
        <zip>611 41</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTHROHELP, s.r.o. /ID# 167001</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus /ID# 165190</name>
      <address>
        <city>Vejle</city>
        <state>Syddanmark</state>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki Univ Central Hospital /ID# 165794</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiljava Medical Research /ID# 165793</name>
      <address>
        <city>Hyvinkaa</city>
        <zip>05800</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Eloi /ID# 166308</name>
      <address>
        <city>Montpellier CEDEX 5</city>
        <state>Herault</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux-Hopital Pellegrin /ID# 166309</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Tours - Hopital Trousseau /ID# 165109</name>
      <address>
        <city>Chambray Les Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumazentrum Ruhrgebiet /ID# 165148</name>
      <address>
        <city>Herne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44649</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff Klinik GmbH /ID# 165158</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charit Centrm Innr Medizn mit /ID# 165153</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumaforschungszentrum II /ID# 165146</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revita Reumatologiai Rendelo /ID# 164724</name>
      <address>
        <city>Budapest</city>
        <zip>1027</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen /ID# 165674</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mentahaz Maganorvosi Kozpont /ID# 165066</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Medical Center Orvosi-es Fogorvosi Kozpont /ID# 164741</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant Orsola Malpighi /ID# 165692</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Paolo Giaccone /Id# 165663</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST G. Pini /ID# 165715</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Senese /ID# 165716</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Occupational and Environmental Health /ID# 164380</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <zip>8078556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital /ID# 165683</name>
      <address>
        <city>Maebashi-shi</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Asahikawa Medical Center /ID# 164566</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <zip>070-8644</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagawa University Hospital /ID# 167517</name>
      <address>
        <city>Kita-gun</city>
        <state>Kagawa</state>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital /ID# 165304</name>
      <address>
        <city>Matsumoto-shi</city>
        <state>Nagano</state>
        <zip>〒390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Okayama Hospital /ID# 164376</name>
      <address>
        <city>Okayama-shi</city>
        <state>Okayama</state>
        <zip>7008607</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHO Osaka Minami Med Ctr /ID# 164365</name>
      <address>
        <city>Kawachinagano-shi</city>
        <state>Osaka</state>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital /ID# 165253</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>545-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital /ID# 166033</name>
      <address>
        <city>Suita-shi</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University Hospital /ID# 164577</name>
      <address>
        <city>Iruma-gun</city>
        <state>Saitama</state>
        <zip>350-0451</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Koshigaya Hospital /ID# 165809</name>
      <address>
        <city>Koshigaya-shi</city>
        <state>Saitama</state>
        <zip>343-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokushima University Hospital /ID# 165108</name>
      <address>
        <city>Tokushima-shi</city>
        <state>Tokushima</state>
        <zip>770-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital /ID# 164738</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8431</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Luke's International Hospital /ID# 165219</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daido Hospital /ID# 163886</name>
      <address>
        <city>Nagoya</city>
        <zip>457-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kochi Medical School Hospital /ID# 164460</name>
      <address>
        <city>Nankoku-shi</city>
        <zip>783-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Saiseikai Outpatient Center Hospital /ID# 165595</name>
      <address>
        <city>Okayama</city>
        <zip>700-0013</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital /ID# 164561</name>
      <address>
        <city>Jung-gu</city>
        <state>Daejeon Gwang Yeogsi</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center /ID# 165114</name>
      <address>
        <city>Incheon</city>
        <state>Incheon Gwang Yeogsi</state>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital /ID# 164541</name>
      <address>
        <city>Gwangju</city>
        <state>Jeonranamdo</state>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospi /ID# 165811</name>
      <address>
        <city>Seongdong-gu</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cath Univ Seoul St Mary's Hosp /ID# 164549</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyunghee University Hospital at Gangdong /ID# 164569</name>
      <address>
        <city>Seoul</city>
        <zip>02447</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center /ID# 164557</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen /ID# 165681</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden /ID# 166937</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital /ID# 169242</name>
      <address>
        <city>Hamilton</city>
        <state>Waikato</state>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital /ID# 169241</name>
      <address>
        <city>Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Nasz Lekarz /ID# 166023</name>
      <address>
        <city>Toruń</city>
        <state>Kujawsko-pomorskie</state>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osteo-Medic S.C. /ID# 165646</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ETYKA-Osrodek Badan Klinicznyc /ID# 165634</name>
      <address>
        <city>Olsztyn</city>
        <state>Warminsko-mazurskie</state>
        <zip>10-117</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Portugues De Reumatologia /ID# 168314</name>
      <address>
        <city>Lisbon</city>
        <state>Lisboa</state>
        <zip>1050-034</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Ocidental, EPE /ID# 168312</name>
      <address>
        <city>Lisbon</city>
        <state>Lisboa</state>
        <zip>1349-019</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Vila Nova Gaia/Espinho, EPE /ID# 168313</name>
      <address>
        <city>Vila Nova De Gaia</city>
        <state>Porto</state>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital CUF Descobertas /ID# 168311</name>
      <address>
        <city>Lisbon</city>
        <zip>1998-018</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidade Local De Saude Do Alto Minho /ID# 168310</name>
      <address>
        <city>Viana Do Castelo</city>
        <zip>4901-858</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Un. Marques de Valdecilla /ID# 165028</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Parc de Salut del Mar /ID# 165027</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corp Sanit Parc Tauli Sabadell /ID# 165029</name>
      <address>
        <city>Barcelona</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skanes Universitetssjukhus /ID# 165712</name>
      <address>
        <city>Malmö</city>
        <state>Skane Lan</state>
        <zip>214 28</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reumatologkliniken /ID# 165713</name>
      <address>
        <city>Vaesteras</city>
        <zip>721 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warrington and Halton Hospitals NHS Foundation Trust /ID# 166202</name>
      <address>
        <city>Warrington</city>
        <state>Cheshire West And Chester</state>
        <zip>WA5 1QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whipps Cross Univ Hospital /ID# 165150</name>
      <address>
        <city>London</city>
        <state>London, City Of</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich Univ Hosp /ID# 165149</name>
      <address>
        <city>Norwich</city>
        <state>Norfolk</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal National Hosp for Rheuma /ID# 165147</name>
      <address>
        <city>Bath</city>
        <zip>BA1 1RL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary /ID# 165152</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>June 5, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <disposition_first_submitted>November 12, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>November 21, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 25, 2019</disposition_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Upadacitinib</keyword>
  <keyword>ABT-494</keyword>
  <keyword>Ankylosing Spondylitis (AS)</keyword>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Upadacitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

